TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Arecor Therapeutics PLC ( (GB:AREC) ) has issued an update.
Arecor Therapeutics plc has announced a change in its auditor, appointing PKF Littlejohn LLP to succeed Grant Thornton UK LLP following a formal tender process. This change is part of the company’s ongoing efforts to ensure robust financial oversight, with PKF set to audit the financial statements for the year ending December 2025. The appointment will be subject to shareholder approval at the 2026 Annual General Meeting, reflecting Arecor’s commitment to transparency and effective governance.
Spark’s Take on GB:AREC Stock
According to Spark, TipRanks’ AI Analyst, GB:AREC is a Neutral.
Arecor Therapeutics PLC shows potential with strong technical momentum and positive corporate events, but ongoing financial challenges and an unattractive valuation score due to losses and lack of dividends weigh on the overall score. The company’s strategic initiatives in R&D and executive confidence are promising, but caution is advised due to high volatility and financial instability typical of biotech firms.
To see Spark’s full report on GB:AREC stock, click here.
More about Arecor Therapeutics PLC
Arecor Therapeutics plc is a biopharmaceutical company focused on transforming patient care by bringing innovative medicines to market. The company enhances existing therapeutic products through its proprietary technology platform, Arestat™, and develops a portfolio of products in diabetes and other indications. Arecor collaborates with leading pharmaceutical and biotechnology companies to deliver therapeutic solutions.
Average Trading Volume: 34,787
Technical Sentiment Signal: Hold
Current Market Cap: £22.28M
See more insights into AREC stock on TipRanks’ Stock Analysis page.